We welcome the submission of abstracts in the following scientific tracks:

- **TRACK 1** - Leishmaniasis: Basic Science, Translational Research and Vaccine Development
- **TRACK 2** - Advances in R&D and access, diagnosis and Treatment for Leishmaniasis
- **TRACK 3** - Leishmaniasis Prevention, Epidemiology, Vector Control and Elimination
- **TRACK 4** – The impact of Covid-19 on Leishmaniasis research

The tracks shall cover cutaneous, mucocutaneous, and visceral leishmaniasis forms, post-kalaazar dermal leishmaniasis, HIV/VL co-infection, as well as ethics and regulatory issues.

**SUBMISSION**

Abstract submission deadline is on 27th August 2021 at 11:30pm East Africa Time (EAT)

All abstracts must be received through the online abstract submission form on or before the deadline.

Participants can submit abstracts via email to leap@dndi.org
Leishmaniasis is a neglected tropical disease (NTD) affecting over one billion people at risk of infection worldwide, with 1 million cases estimated annually. It is a complex disease that presents in several forms—visceral, cutaneous, mucocutaneous, and post-kala-azar dermal leishmaniasis.

Diagnosis of leishmaniasis is invasive and requires trained personnel. Currently available RDTs have limitations and confirmatory diagnosis of leishmaniasis is invasive, requiring trained personnel. Current treatment options are toxic, expensive, and not field-adapted. Response to treatment usually depends on several factors, including the form of the disease, other co-existing infections as well as nutritional and immunological status of the host.

**ABOUT THE LEAP SCIENTIFIC CONFERENCE**

The LEAP Conference brings together scientists, researchers, policy makers, public health practitioners and civil society to discuss the diagnosis, treatment, prevention, control, and elimination of leishmaniasis.

**CONFERENCE ORGANIZERS**

**Drugs for Neglected Diseases initiative (DNDi)**

DNDi is a patient-driven, non-profit drug R&D organization that develops lifesaving medicines for patients affected by neglected diseases. DNDi works to deliver new treatments for leishmaniasis, human African trypanosomiasis, Chagas disease, specific filarial infections, mycetoma, paediatric HIV, and hepatitis C. Since inception in 2003, DNDi has delivered 8 treatments for 5 deadly diseases. Among these treatments is sodium stibogluconate and paromomycin, a combination therapy for visceral leishmaniasis in Africa.

**Leishmaniasis East Africa Platform (LEAP)**

Founded in 2003, in Khartoum, Sudan by DNDi, LEAP is a clinical research network bringing together experts from leishmaniasis endemic eastern African countries to facilitate clinical testing and improved access to better treatments for leishmaniasis in the region. The platform aims to strengthen clinical research capacity, which is lacking in part due to the remoteness and geographic spread of the patients mostly living in remote regions of Africa.